Trial Profile
A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2023 Status changed from recruiting to completed.
- 08 Mar 2022 Planned End Date changed from 1 May 2022 to 30 Nov 2022.
- 08 Mar 2022 Planned primary completion date changed from 1 Feb 2022 to 30 Sep 2022.